Literature DB >> 6138365

Acute reduction in human platelet alpha 2-adrenoreceptor affinity for agonist by endogenous and exogenous catecholamines.

A S Hollister, G A FitzGerald, J H Nadeau, D Robertson.   

Abstract

The binding characteristics of l-epinephrine to intact human platelets were assessed under conditions of physiological and pharmacological variations in plasma catecholamine concentration. In competition with the alpha 2-adrenoreceptor antagonist yohimbine, mean platelet receptor affinity for l-epinephrine was decreased 3.4-fold after 2 h of upright posture and exercise. This change in agonist affinity correlated significantly with the increases in plasma epinephrine and norepinephrine that were stimulated by upright posture and exercise. Supine subjects infused with l-norepinephrine or l-epinephrine for 2 h also averaged a 3.3- and 2.7-fold decrease in platelet alpha 2-adrenoreceptor affinity for agonist with no change in receptor number or antagonist affinity. The alpha 2-adrenoreceptor agonist affinity changes were specific for alpha-agonists since they were blocked by phentolamine, and incubation with 10(-5) M isoproterenol produced no change in alpha 2-adrenoreceptor affinity for l-epinephrine. In vitro exposure of intact human platelets to 10(-6) to 10(-10) M l-epinephrine for 2 h produced a concentration-related decrease in alpha 2-adrenoreceptor affinity for agonist. In all three paradigms, average slope factors approached 1.0 as affinity decreased, which is consistent with a heterogeneous receptor population that becomes more homogeneous after agonist exposure. Incubation of platelet-rich plasma with 10(-6) to 10(-8) M l-epinephrine resulted in a dose- and time-related loss of aggregatory response to l-epinephrine; this demonstrates that agonist affinity changes are correlated with changes in receptor sensitivity. These observations demonstrate that physiological variations in plasma catecholamines acutely modulate the intact human platelet alpha 2-adrenoreceptor's affinity for agonist, and can thereby alter the sensitivity of platelets to alpha 2-adrenergic agonist.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138365      PMCID: PMC370434          DOI: 10.1172/JCI111106

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine.

Authors:  K H Jakobs; W Saur; G Schultz
Journal:  J Cyclic Nucleotide Res       Date:  1976 Nov-Dec

2.  Agonist-specific effects of monovalent and divalent cations on adenylate cyclase-coupled alpha adrenergic receptors in rabbit platelets.

Authors:  B S Tsai; R J Lefkowitz
Journal:  Mol Pharmacol       Date:  1978-07       Impact factor: 4.436

3.  Characterization of the human platelet alpha-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition.

Authors:  R W Alexander; B Cooper; R I Handin
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

4.  Agonist regulation of the human platelet alpha-adrenergic receptor.

Authors:  B Cooper; R I Handin; L H Young; R W Alexander
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

5.  Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation.

Authors:  J A Grant; M C Scrutton
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

6.  Agonist-specific effects of guanine nucleotides on alpha-adrenergic receptors in human platelets.

Authors:  B S Tsai; R J Lefkowitz
Journal:  Mol Pharmacol       Date:  1979-07       Impact factor: 4.436

7.  Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities.

Authors:  P N Walsh
Journal:  Br J Haematol       Date:  1972-02       Impact factor: 6.998

8.  Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process.

Authors:  Y F Su; T K Harden; J P Perkins
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

9.  The effects of alpha adrenergic agents on human platelet aggregation.

Authors:  C Y Hsu; D R Knapp; P V Halushka
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

10.  Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man.

Authors:  D Robertson; G A Johnson; R M Robertson; A S Nies; D G Shand; J A Oates
Journal:  Circulation       Date:  1979-04       Impact factor: 29.690

View more
  7 in total

1.  Effect of a 7-day treatment with idazoxan and its 2-methoxy derivative RX 821002 [correction of RX 821001] on alpha 2-adrenoceptors and non-adrenoceptor idazoxan binding sites in rabbits.

Authors:  M Portillo; M Reverte; D Langin; J M Senard; M A Tran; M Berlan; J L Montastruc
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

2.  Plasma catecholamine modulation of alpha 2 adrenoreceptor agonist affinity and sensitivity in normotensive and hypertensive human platelets.

Authors:  A S Hollister; J Onrot; S Lonce; J H Nadeau; D Robertson
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

3.  Alterations in platelet alpha 2-adrenoceptors by aspirin.

Authors:  J L Mehta; P Mehta; D Lawson
Journal:  Agents Actions       Date:  1988-06

4.  Altered adrenoceptor responsiveness during adrenaline infusion but not during mental stress: differences between receptor subtypes and tissues.

Authors:  P T Larsson; A Martinsson; G Olsson; P Hjemdahl
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

5.  Adenylate-cyclase activity in platelets of patients with obsessive-compulsive disorder.

Authors:  D Marazziti; S Baroni; L Palego; I Masala; G Consoli; M Catena Dell'osso; G Giannaccini; A Lucacchini
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

6.  Direct relationship between mononuclear leukocyte and lung beta-adrenergic receptors and apparent reciprocal regulation of extravascular, but not intravascular, alpha- and beta-adrenergic receptors by the sympathochromaffin system in humans.

Authors:  S B Liggett; J C Marker; S D Shah; C L Roper; P E Cryer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

7.  In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury.

Authors:  Christoph Tschuor; Lars M Asmis; Philipp M Lenzlinger; Martina Tanner; Luc Härter; Marius Keel; Reto Stocker; John F Stover
Journal:  Crit Care       Date:  2008-06-18       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.